# REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

Study · id `cardio:ct-nct06788535` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06788535](<https://clinicaltrials.gov/study/NCT06788535>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06788535

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 204 participants.

## Technical summary

Registry record NCT06788535. Allocation not applicable; no masking; primary purpose diagnostic. Start 2025-01-14 (actual); primary completion 2026-04-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 204 participants (enrolled count; ClinicalTrials.gov record NCT06788535, source copy `cardio:ctgov-nct06788535-2026-04-30`, retrieved 2026-10-31)
- Started: 2025-01-14 (actual) (ClinicalTrials.gov record NCT06788535, source copy `cardio:ctgov-nct06788535-2026-04-30`, retrieved 2026-10-31)
- Primary completion: 2026-04-08 (actual) (ClinicalTrials.gov record NCT06788535, source copy `cardio:ctgov-nct06788535-2026-04-30`, retrieved 2026-10-31)
- Completion: 2026-04-09 (actual) (ClinicalTrials.gov record NCT06788535, source copy `cardio:ctgov-nct06788535-2026-04-30`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT06788535, source copy `cardio:ctgov-nct06788535-2026-04-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06788535-2026-04-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
- Acronym: REVEAL
- Condition: Cardiac Amyloidosis
- Intervention (Drug): I-124 evuzamitide
- Lead sponsor: Sharmila Dorbala
- Lead sponsor class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

## Provenance

Content hash: f6250999f3f8481c5db2ae5a27049c4857b117edd979220719551618ab38bb56
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
